Brief: Brii Biosciences Announces Positive Data From Study Of Co's COVID-19 Neutralizing Antibody Therapy
09/06/2022 14:19
June 9 (Reuters) - Brii Biosciences Ltd 2137.HK :
* ANNOUNCES POSITIVE DATA FROM A RANDOMIZED, SINGLE-BLIND
CLINICAL
STUDY OF CO'S COVID-19 NEUTRALIZING ANTIBODY THERAPY
Source text for Eikon: ID:nHKS3RHL2Q
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR